Medtronic plc (MDT) Financial Statements
Historical financial data — 45 statements covering FY2016–FY2026
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter h...
Medtronic plc's revenue increased 8.4% year over year, from $33.54B to $36.36B.
Net income increased 3.0% over the same period, from $4.66B to $4.80B.
Over the 10-year period from FY2016 to FY2026, revenue grew by 26% in total.
Operating cash flow grew 4.1% to $7.33B.
Medtronic plc maintains a healthy net profit margin of 13.2%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2025 | $8.40B+6.2% | $1.27B | $5.46B | $1.59B | $958.0M | $90.04B | $28.33B | $48.49B |
| Q3 FY2025 | $8.29B-1.3% | $1.29B | $5.51B | $1.65B | $2.57B | $89.97B | $26.61B | $49.39B |
| Q4 FY2025 | $8.93B+7.7% | $1.06B | $5.78B | $1.44B | $2.53B | $91.68B | $28.52B | $48.02B |
| Q1 FY2026 | $8.58B-3.9% | $1.04B | $5.58B | $1.45B | $1.09B | $90.97B | $28.61B | $47.89B |
| Q2 FY2026 | $8.96B+4.5% | $1.37B | $5.90B | $1.69B | $925.0M | $91.35B | $29.10B | $48.65B |
| Q3 FY2026 | $9.02B+0.6% | $1.14B | $5.76B | $1.46B | $2.74B | $91.48B | $28.07B | $48.98B |
| Q4 FY2026 | $9.81B+8.7% | $1.24B | $6.41B | $1.87B | $2.57B | N/A | N/A | N/A |
| Q1 FY2027 | $9.76B-0.5% | $1.47B | $6.34B | $1.76B | $1.79B | N/A | N/A | N/A |
Balance Sheet Summary (Q3 FY2026)
Medtronic plc (MDT) Financial Statements & Revenue History
Medtronic plc (MDT) is a US-listed stock operating in the Healthcare sector, specifically the Medical Devices industry trading at $94.80 with a market capitalization of $121. This page provides 45 historical financial statements for Medtronic plc, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Medtronic plc reported revenue of $36.4 billion, representing 8.4% year-over-year growth. The net profit margin of 13.2% indicates moderate profitability..
MDT Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Medtronic plc's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether MDT is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track MDT's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Medtronic plc converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of MDT's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use MDT Financial Data
Investors use Medtronic plc's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare MDT's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how MDT's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View MDT's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Medtronic plc's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.MDT trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.